Lineage Cell Therapeutics (LCTX) Minority Interest (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Minority Interest of -$1.2 million for Q1 2026, up 14.06% year-over-year from -$1.0 million in Q1 2025, and up 1.91% quarter-over-quarter from -$1.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Minority Interest (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Minority Interest history runs 17 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- In Q1 2026, Minority Interest rose 14.06% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$1.2 million (up 14.06% YoY), while the FY2025 annual figure was -$1.2 million, up 12.13% from the prior year.
- Minority Interest for Q1 2026 stood at -$1.2 million, up from -$1.2 million in the prior quarter.
- The five-year high for Minority Interest was -$1.2 million in Q1 2026, with the low at -$1.5 million in Q3 2023.
- The 5-year median for Minority Interest is -$1.4 million (2024), against an average of -$1.4 million.
- The sharpest annual moves came in 2022 and 2026: Minority Interest dropped 24.22% in 2022, then gained 14.06% in 2026.
- Lineage Cell Therapeutics' Minority Interest stood at -$1.4 million in 2022, then increased by 0.5% to -$1.4 million in 2023, then grew by 1.93% to -$1.4 million in 2024, then climbed by 12.13% to -$1.2 million in 2025, then climbed by 1.91% to -$1.2 million in 2026.
- Business Quant data shows LCTX's Minority Interest at -$1.2 million in Q1 2026, -$1.2 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.12 Mn |
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Jun 30, 2025 | -1.27 Mn |
| Mar 31, 2025 | -1.37 Mn |
| Dec 31, 2024 | -1.37 Mn |
| Sep 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | -1.41 Mn |
| Dec 31, 2023 | -1.40 Mn |
| Sep 30, 2023 | -1.46 Mn |
| Jun 30, 2023 | -1.41 Mn |
| Mar 31, 2023 | -1.44 Mn |
| Dec 31, 2022 | -1.40 Mn |
| Sep 30, 2022 | -1.40 Mn |
| Jun 30, 2022 | -1.35 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -1.32 Mn |
| Sep 30, 2021 | -1.12 Mn |